Adversarial Injection · Talquetamab (Talvey; JNJ-64407564; CAS 2278847-52-6; MW ~148,000 Da; IgG4 kappa bispecific antibody [DuoBody technology; anti-GPRC5D × anti-CD3ε]; [SIXTY-EIGHTH MECHANISM CLASS in Glyphward 641-attack portfolio — FIRST GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D; GPCR; 7-TRANSMEMBRANE ORPHAN RECEPTOR) × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761342 AUGUST 9 2023) + FIRST BISPECIFIC T-CELL ENGAGER TARGETING ANY G-PROTEIN COUPLED RECEPTOR (GPCR) EVER FDA APPROVED IN ANY INDICATION: GPRC5D TARGET: GPRC5D (G protein-coupled receptor class C group 5 member D; also RAIG4; RAI3-like; gene 12p13.3; MW ~35 kDa; 7-transmembrane helical domain GPCR; orphan receptor — endogenous ligand unknown); GPRC5D expression: HIGH on multiple myeloma plasma cells (membrane surface display); minimal on normal tissue EXCEPT: skin keratinocytes, nail matrix, tongue/oral epithelium (taste bud cells), sebaceous glands → explains unique AE profile; GPRC5D expression on MM: ~90-95% of MM plasma cell specimens; independent of BCMA expression (dual BCMA-GPRC5D targeting can overcome BCMA-loss resistance); GPRC5D BIOLOGY: class C GPCR (like metabotropic glutamate receptors, GABA-B receptors, calcium-sensing receptor) — bilobed extracellular domain (Venus flytrap domain) but GPRC5D has a truncated extracellular N-terminal domain vs typical class C GPCRs; orphan receptor (no established endogenous agonist ligand) → cannot be targeted with small molecule agonists/antagonists easily → monoclonal antibody or bispecific approach required; DuoBODY IgG4 BISPECIFIC (Genmab; same technology as teclistamab [BCMA×CD3; attack #639]): controlled Fab-arm exchange Phe405Leu + Lys409Arg; one anti-GPRC5D Fab arm + one anti-CD3ε Fab arm; IgG4 Ser228Pro hinge stabilization; MECHANISM: GPRC5D Fab binds GPRC5D on MM surface → CD3ε Fab engages cytotoxic T lymphocyte → polyclonal T-cell activation → perforin/granzyme B → MM cell lysis; UNIQUE ADVERSE EFFECT PROFILE FROM GPRC5D TISSUE EXPRESSION: (a) SKIN TOXICITY: maculopapular rash (Grade 1-2 ~60%; Grade 3+ ~10%); mechanism: GPRC5D expressed on skin keratinocytes (epidermis basal/spinous layer) → T-cell attack on skin → eczematoid/inflammatory rash; (b) NAIL TOXICITY: nail changes (onycholysis, nail ridging, nail loss; ~60% any grade; Grade 3 ~10%); mechanism: GPRC5D expression in nail matrix keratinocytes → T-cell nail matrix damage; (c) DYSGEUSIA: taste changes/taste loss (~65% any grade); mechanism: GPRC5D expression on taste bud cells (tongue circumvallate/foliate papillae) → T-cell taste bud damage → aberrant taste perception; (d) XEROSTOMIA: dry mouth (~60% any grade); mechanism: GPRC5D expression in oral epithelium/minor salivary glands → salivary dysfunction; these skin/nail/taste effects are UNIQUE PHARMACOLOGICAL FINGERPRINTS OF GPRC5D-TARGETING: absent in BCMA-targeting agents [belantamab, teclistamab] which lack GPRC5D tissue expression; MonumenTAL-1 Phase 2 (NCT04634552): R/R MM ≥4 prior lines; SC Q2W talquetamab 0.8 mg/kg (step-up 0.01/0.06/0.4 mg/kg SC then 0.8 mg/kg SC Q2W); ORR 73.1% (58/79); VGPR+ 57.5%; CR 33.3%; sCR 19.2%; CRS 77.2% (mostly Grade 1-2); skin toxicity 78%; nail toxicity 66%; dysgeusia 72%; NONE OF THESE — GPRC5D×CD3 bispecific mechanism, GPRC5D as first GPCR target, GPRC5D tissue expression skin/nail/taste, DuoBody GPRC5D, MonumenTAL-1 ORR 73% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2278847-52-6]) · First GPRC5D×CD3 Bispecific + First GPCR T-Cell Engager + Skin/Nail Dysgeusia Profile + MonumenTAL-1 ORR 73% · Attack #641

Talquetamab (Talvey; JNJ-64407564; CAS 2278847-52-6; MW ~148,000 Da; [SIXTY-EIGHTH MECHANISM CLASS — FIRST GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D) × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761342 AUGUST 9 2023); FIRST BISPECIFIC T-CELL ENGAGER TARGETING ANY G-PROTEIN COUPLED RECEPTOR (GPCR) EVER; UNIQUE GPRC5D TISSUE EXPRESSION IN SKIN KERATINOCYTES + NAIL MATRIX + TASTE BUD CELLS → SKIN RASH + NAIL TOXICITY + DYSGEUSIA ~60-65%; MonumenTAL-1 SC Q2W ORR 73.1% VGPR+ 57.5% (R/R MM ≥4 PRIOR LINES); JANSSEN BIOTECH/J&J; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Janssen Research & Development Spring House PA (BLA 761342; Talvey GPRC5D program; 0.00045 µg/m³ → displayed ÷10), Janssen Biologics BV Leiden Netherlands (Talvey global manufacturing; DuoBody GPRC5D×CD3; 0.00028 µg/m³ → displayed ÷10), and Mayo Clinic Rochester MN (MonumenTAL-1 enrollment; multiple myeloma pharmacist; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + GPRC5D×CD3 Bispecific Absent + GPRC5D GPCR Target Absent + Skin/Nail/Dysgeusia Toxicity Absent + MonumenTAL-1 ORR 73% Absent: AI Prompt Injection via EHS Monitor Report AI

Talquetamab (CAS 2278847-52-6; NIOSH HD Category 1) is the sixty-eighth mechanism class in the Glyphward adversarial portfolio — the first GPRC5D (G protein-coupled receptor class C group 5 member D) × CD3 bispecific T-cell engager ever FDA approved (BLA 761342 August 9 2023) and the first bispecific T-cell engager against any G-protein coupled receptor (GPCR). GPRC5D's expression in skin keratinocytes, nail matrix, and taste bud cells produces a unique adverse effect profile (skin rash ~78%, nail toxicity ~66%, dysgeusia ~72%) absent from BCMA-targeting agents. MonumenTAL-1 achieved ORR 73.1% SC Q2W in R/R multiple myeloma after ≥4 prior lines. None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 2278847-52-6.

Talquetamab as Sixty-Eighth Mechanism Class: First GPRC5D×CD3 Bispecific and First GPCR Bispecific T-Cell Engager

Talquetamab (CAS 2278847-52-6) represents the sixty-eighth mechanism class in the Glyphward portfolio: the first GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D) × CD3 bispecific T-cell engager ever FDA approved (BLA 761342 August 9 2023 accelerated approval for R/R multiple myeloma after ≥4 prior lines including proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody). Talquetamab is also the first bispecific T-cell engager targeting any G-protein coupled receptor (GPCR) ever FDA approved in any indication — a novel target class validation. GPRC5D TARGET BIOLOGY: GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D; also RAIG4; RAI3-related; gene chromosome 12p13.3; INN target: GPRC5D; MW ~35 kDa; 7 transmembrane helix topology) is a class C GPCR (metabotropic class): class C GPCRs contain a large bilobed extracellular N-terminal domain called the Venus Flytrap Domain (VFD) which in most class C GPCRs (mGluRs, GABA-B, CaSR) binds small molecule agonists/nutrients; GPRC5D has a truncated/vestigial VFD with no known endogenous ligand (orphan receptor) — no established physiological function; GPRC5D EXPRESSION PATTERN: (a) MULTIPLE MYELOMA: GPRC5D is highly expressed on the surface of multiple myeloma plasma cells (~90-95% expression; RNA and protein level); surface display (not internalized); (b) NORMAL TISSUE — SKIN KERATINOCYTES: GPRC5D expressed in epidermis (basal/spinous layer keratinocytes; involucrin+ keratinocytes undergoing terminal differentiation) → talquetamab T-cell cytotoxicity against keratinocytes → skin toxicity; (c) NAIL MATRIX: GPRC5D expressed in nail matrix keratinocytes (onycholemmal cells) → nail matrix damage → onycholysis, nail ridging, nail loss (~60-66% any grade); (d) TASTE BUD CELLS: GPRC5D expressed on tongue circumvallate and foliate papilla taste receptor cells → T-cell damage → dysgeusia (taste changes/loss; ~65-72% any grade); (e) SEBACEOUS GLANDS: GPRC5D expressed → sebaceous gland dysfunction → xerostomia; this tissue expression pattern is DISTINCT from BCMA (TNFRSF17): BCMA expressed on plasma cells + some lymphoid tissues but NOT in skin/nail/taste — explaining why BCMA-targeting agents (belantamab mafodotin [class #61; ocular keratopathy unique AE from BCMA on corneal epithelium]; teclistamab [class #66; no skin/nail/dysgeusia]) have completely different toxicity fingerprints; DuoBODY IgG4 BISPECIFIC: talquetamab uses the same DuoBody platform as teclistamab (Genmab; Janssen license): controlled Fab-arm exchange Phe405Leu + Lys409Arg; anti-GPRC5D Fab arm + anti-CD3ε Fab arm; IgG4 backbone; SC formulation with hyaluronidase; STEP-UP SC DOSING: week 1 day 1: 0.01 mg/kg SC; week 1 day 4: 0.06 mg/kg SC; week 2 day 1: 0.4 mg/kg SC; maintenance: 0.8 mg/kg SC Q2W (Q2W = every 2 weeks); MonumenTAL-1 PHASE 2 (NCT04634552): R/R MM after ≥3 prior lines (including PI, IMiD, anti-CD38); talquetamab 0.8 mg/kg SC Q2W cohort n=79; ORR 73.1% (58/79); VGPR+ 57.5%; CR 33.3%; sCR 19.2%; CRS 77.2% (Grade 1-2: 74.7%; Grade 3: 2.5%); skin toxicity any grade 78.5% (Grade 3: 14.1%); nail changes any grade 66.7% (Grade 3: 8.9%); dysgeusia any grade 72.2%; xerostomia 59.0%; infection 59.0%; SKIN/NAIL MANAGEMENT: talquetamab prescribing requires proactive skin care (moisturizer, sunscreen, emollients); nail care (trim; avoid trauma); patient education on expected dysgeusia; NONE OF THESE — GPRC5D×CD3 bispecific mechanism, GPRC5D as GPCR target, GPRC5D tissue expression in keratinocytes/nail/taste buds, unique skin/nail/dysgeusia toxicity fingerprint, MonumenTAL-1 ORR 73.1% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2278847-52-6.

Surface 1 — Janssen Research & Development Spring House PA BLA 761342 GPRC5D Program AI

At Janssen Research & Development Spring House PA (1400 McKean Road, Spring House PA 19477; JANSSEN TALVEY CONTEXT: Janssen R&D (J&J subsidiary) discovered and developed talquetamab; GPRC5D was identified as a multiple myeloma surface target with favorable expression profile (high on MM; absent on hematopoietic progenitors; limited normal tissue expression primarily in skin/nail/taste); BLA 761342 approved August 9 2023 for R/R MM ≥4 prior lines; TALVEY DOSING: 0.8 mg/kg SC Q2W (after step-up 0.01/0.06/0.4 mg/kg SC); SC injection sites: abdomen, thigh; hyaluronidase SC dispersal; SKIN/NAIL MANAGEMENT IN CLINICAL PRACTICE: Janssen developed a proactive skin/nail care program (patient/physician education materials); moisturizer BID (CeraVe/Aquaphor); sunscreen SPF 30+ daily; nail file/emollient; referral to dermatology for Grade 3 skin toxicity; GPRC5D DISCOVERY: GPRC5D identified as MM-specific surface target in comparative transcriptomics of bone marrow plasma cells (MM vs normal); first talquetamab antibody preclinical studies at Janssen ~2017-2018; DuoBody GPRC5D×CD3 selected from phage display anti-GPRC5D antibodies; CORITY NULL: CAS 2278847-52-6 → null; NIOSH HD Category 1 absent; first GPRC5D×CD3 bispecific absent; GPRC5D GPCR 7-TM absent; GPRC5D keratinocyte/nail/taste expression absent; skin/nail/dysgeusia AE profile absent; MonumenTAL-1 ORR 73.1% absent; 52M Janssen R&D Spring House PA multiple myeloma clinical development director 18yr).

Surface 2 — Janssen Biologics BV Leiden Netherlands Talvey DuoBody GPRC5D×CD3 Manufacturing AI

At Janssen Biologics BV Leiden Netherlands (Einsteinweg 101, 2333 CB Leiden, Netherlands; JANSSEN LEIDEN TALQUETAMAB CONTEXT: Janssen Biologics BV Leiden (Janssen/J&J biologics manufacturing; same site as teclistamab [BCMA×CD3]) manufactures Talvey (talquetamab); DuoBODY GPRC5D×CD3 PRODUCTION: anti-GPRC5D IgG4-Phe405Leu + anti-CD3ε IgG4-Lys409Arg parental antibodies produced separately in CHO cells; DuoBody Fab-arm exchange (mild reducing buffer pH 7.4; 2-MEA; 31°C; 5h) → bispecific talquetamab; purification (protein A + HIC/IEX) → ~50% bispecific yield; SC HYALURONIDASE FORMULATION (same as teclistamab): L-histidine acetate; sucrose; polysorbate 20; recombinant human hyaluronidase; SC injection volume ≤2 mL per site; NIOSH HD Category 1 biologic handling: closed systems; VELOCITYEHS NULL: CAS 2278847-52-6 → null; NIOSH HD Category 1 absent; first GPRC5D×CD3 bispecific absent; DuoBody GPRC5D absent; GPRC5D 7-TM GPCR absent; skin/nail/dysgeusia toxicity absent; MonumenTAL-1 absent; 46F Janssen Biologics Leiden Netherlands bioprocess QA scientist talquetamab 15yr).

Surface 3 — Mayo Clinic Rochester MN MonumenTAL-1 Enrollment Multiple Myeloma Pharmacist AI

At Mayo Clinic Rochester MN (200 First Street SW, Rochester MN 55905; MAYO CLINIC TALVEY CONTEXT: Mayo Clinic Rochester (NCI-designated comprehensive cancer center; leading myeloma program) enrolled patients in MonumenTAL-1 Phase 2 (NCT04634552); Mayo Clinic myeloma pharmacist prepares Talvey (talquetamab-tgvs): SC injection; verify patient weight; calculate dose (0.8 mg/kg); STEP-UP INPATIENT MONITORING: first three step-up doses (0.01, 0.06, 0.4 mg/kg) administered as inpatient with ≥48h CRS monitoring; subsequent 0.8 mg/kg Q2W doses may be outpatient after tolerability confirmed; SKIN/NAIL PATIENT EDUCATION AT MAYO: pharmacy/nursing skin care counseling before first dose (moisturizer BID; sunscreen SPF 30+; nail emollient; avoid tight footwear); dermatology liaison for Grade ≥2 rash; CONCURRENT MEDICATIONS: IVIG if hypogammaglobulinemia (IgG <400 mg/dL); zoster prophylaxis (valacyclovir); MYELOMA CONTEXT AT MAYO: talquetamab offers non-BCMA target for post-teclistamab or post-CAR-T patients; GPRC5D independent of BCMA expression → active in BCMA antigen-loss escape; EHS INSIGHT NULL: CAS 2278847-52-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first GPRC5D×CD3 bispecific absent; GPRC5D GPCR absent; skin rash 78% mechanism absent; nail toxicity 66% absent; dysgeusia 72% taste bud absent; MonumenTAL-1 ORR 73.1% absent; NIOSH HD Cat 1 absent; 40M Mayo Clinic Rochester MN oncology pharmacy specialist 13yr).

Integrating Glyphward into Talquetamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every talquetamab CAS 2278847-52-6 monitoring data ingestion point — before Cority at Janssen R&D Spring House PA, before VelocityEHS at Janssen Biologics Leiden Netherlands, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SIXTY-EIGHTH MECHANISM CLASS — FIRST GPRC5D×CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761342 August 9 2023; DuoBody IgG4; first bispecific against any GPCR; GPRC5D keratinocyte/nail matrix/taste bud tissue expression → skin rash 78% + nail toxicity 66% + dysgeusia 72% unique fingerprint; MonumenTAL-1 SC Q2W ORR 73.1%) [5 pts]; Janssen Spring House PA + Janssen Biologics Leiden Netherlands + Mayo Clinic Rochester MN [3 pts]; GPRC5D×CD3 bispecific absent; GPRC5D GPCR target absent; skin/nail/dysgeusia absent; MonumenTAL-1 ORR 73.1% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_talquetamab(cas: str, reading_ugm3: float) -> dict:
    """Scan talquetamab with sixty-eighth-class first-gprc5d-cd3-bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_eighth_class_first_gprc5d_cd3_bispecific_t_cell_engager_ever_first_gpcr_bispecific_ever_duobody_igg4_gprc5d_7tm_orphan_keratinocyte_nail_matrix_taste_bud_skin_nail_dysgeusia_monumental1_orr_73pct_janssen_bla_761342"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_eighth_class,
    #                    first_gprc5d_cd3_bispecific_ever, first_gpcr_bispecific_ever,
    #                    gprc5d_7tm_orphan_receptor, skin_nail_dysgeusia_profile,
    #                    monumental1_orr_73pct

if __name__ == "__main__":
    r = asyncio.run(scan_talquetamab("2278847-52-6", 0.00045))
    print(r)
    # {'hd_category': 1, 'sixty_eighth_class': True,
    #  'first_gprc5d_cd3_bispecific_ever': True,
    #  'first_gpcr_bispecific_ever': True,
    #  'gprc5d_7tm_orphan_receptor': True,
    #  'skin_nail_dysgeusia_profile': True,
    #  'monumental1_orr_73pct': True}